{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:05:04Z","timestamp":1791518704400,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020910","name":"Institut de recherche Pierre Fabre SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020910","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115514","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T15:02:19Z","timestamp":1747666939000},"page":"115514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry"],"prefix":"10.1016","volume":"223","author":[{"given":"M.","family":"Bloem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.B.","family":"Aarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.W.P.J.","family":"van den Berkmortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.U.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.A.M.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.D.M.","family":"Boreel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.B.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.A.P.","family":"Hospers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kapiteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.J.","family":"van Not","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Piersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rikhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Stevense-den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.M.","family":"van der Veldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Vreugdenhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.J.M.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.M.","family":"van den Eertwegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115514_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102485","article-title":"Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021","volume":"69","author":"van Not","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2025.115514_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2015.09.013","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies","volume":"53","author":"Ugurel","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115514_bib3","article-title":"Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis","volume":"154","author":"Sandhu","year":"2021","journal-title":"J Neurooncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115514_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33162","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials","volume":"147","author":"van Zeijl","year":"2020","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2025.115514_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115514_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2025.115514_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112922","article-title":"A survival tree of advanced melanoma patients with brain metastases treated with immune checkpoint inhibitors","volume":"15","author":"van Not","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115514_bib8","doi-asserted-by":"crossref","unstructured":"Le Rhun E., Guckenberger M., Smits M., et al. EANO\u2013ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours \u2606. Ann. Oncol. 2021;32(11). doi:10.1016\/j.annonc.2021.07.016.","DOI":"10.1016\/j.annonc.2021.07.016"},{"key":"10.1016\/j.ejca.2025.115514_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115514_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2025.115514_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115514_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":": Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115514_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdw641","article-title":"Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-arm, phase 2, multicentre study","volume":"28","author":"McArthur","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115514_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115514_bib15","article-title":"POLARIS: a phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis","volume":"6","author":"Menzies","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ejca.2025.115514_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1466185","article-title":"Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial","volume":"15","author":"Soria","year":"2025","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115514_bib17","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/neuonc\/noae116","article-title":"Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN\/GEM1802 phase II study)","volume":"26","author":"M\u00e1rquez-Rodas","year":"2024","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2025.115514_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115514_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000707","article-title":"Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases","author":"Ismail","year":"2021","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2025.115514_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2020.11.028","article-title":"Survival outcomes of patients with advanced melanoma from 2013 to 2017: results of a nationwide population-based registry","volume":"144","author":"van Zeijl","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2025.115514_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1016\/j.ejca.2025.115514_bib22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115514_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114202","article-title":"Symptomatic\u201d melanoma brain metastases: a call for clear definitions and adoption of standardized tools","volume":"208","author":"Le Rhun","year":"2024","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2025.115514_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"issue":"36","key":"10.1016\/j.ejca.2025.115514_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02659","article-title":"COLUMBUS 5-year update: a randomized, open-label, Phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-Mutant Melanoma","volume":"40","author":"Dummer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115514_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010643","article-title":"Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry","volume":"6","author":"Zhang","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2025.115514_bib27","unstructured":"European Medicines Agency. EPAR Zelboraf. 2012. Accessed May 3, 2024. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zelboraf-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.ejca.2025.115514_bib28","unstructured":"European Medicines Agency. EPAR Tafinlar. 2013. Accessed May 3, 2024. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tafinlar-epar-product-information_en.pdf\u3009."},{"key":"10.1016\/j.ejca.2025.115514_bib29","unstructured":"European Medicines Agency. EPAR Bravtofi. 2018. Accessed May 3, 2024. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/braftovi-epar-product-information_en.pdf\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2025.115514_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000908","article-title":"Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS","volume":"34","author":"K\u00e4hler","year":"2024","journal-title":"Melanoma Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002965?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925002965?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T20:03:31Z","timestamp":1748894611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925002965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"alternative-id":["S0959804925002965"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115514","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the Dutch Melanoma Treatment Registry","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115514"}}